Elevated serum potassium, commonly known as hyperkalemia, is a condition common in patients with decreased renal function and heart failure and is often exacerbated by those receiving RAAS inhibitors or NSAIDs. Although largely asymptomatic, if left untreated hyperkalemia can result in cardiac dysfunction and even death. Drug development has been minimal over the past 50 years; however, new potassium-binding products from Relypsa/Vifor Fresenius Medical Care Renal Pharma and ZS Pharma/AstraZeneca are anticipated in the major markets under study. These therapies compete directly with an existing binder by offering improvements in safety and efficacy and are expected to significantly increase the value of the hyperkalemia market over the next decade. With these changing market dynamics, companies investing in the space need to understand the competing factors that will influence the commercial success, or failure, of new product launches.
- What market access and reimbursement challenges will the emerging potassium binders face in the G7? Will this influence patient share?
- Will patiromer and zirconium cyclosilicate become blockbusters in the major markets?
- What do key opinion leaders think will be the most promising new therapy to treat chronic and/or acute hyperkalemia?
- What challenges will potassium binders face as a chronic treatment for hyperkalemia?
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
- Hyperkalemia - Landscape & Forecast - Disease Landscape & Forecast
Author(s): Caitlin Koris, MSPH
Caitlin Koris, MSPH, is a business insights analyst on the cardiovascular, metabolic, and renal disorders team at Decision Resources Group. She has developed expertise in chronic kidney disease and related disorders such as bone and mineral metabolism, renal anemia, hyperkalemia, diabetic nephropathy, and kidney transplant.
Prior to joining DRG, Caitlin was a clinical research monitor for oncology phase I and II trials. She obtained her M.S. in public health/health services research (MSPH) from Emory University, where she focused on pharmacoeconomics/outcomes research and healthcare policy. She has conducted research at the U.S. Centers for Disease Control and at the Food and Drug Administration.